Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 72

1.

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

Guancial EA, Rosenberg JE, Sweeney CJ.

Am Soc Clin Oncol Educ Book. 2011 Spring;2011:171-176.

2.

Prostate cancer: cardiovascular risk and androgen deprivation therapy.

Razzak M.

Nat Rev Urol. 2012 Jan 10;9(2):61. doi: 10.1038/nrurol.2011.229. No abstract available.

PMID:
22231292
3.

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW.

J Clin Oncol. 2012 Feb 10;30(5):507-12. doi: 10.1200/JCO.2011.37.7002. Epub 2011 Dec 19.

4.

Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.

Nelson PS.

J Clin Oncol. 2012 Feb 20;30(6):644-6. doi: 10.1200/JCO.2011.39.1300. Epub 2011 Dec 19. No abstract available.

PMID:
22184375
5.

Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.

J Clin Endocrinol Metab. 2012 Feb;97(2):507-16. doi: 10.1210/jc.2011-2189. Epub 2011 Dec 14.

PMID:
22170708
6.

Targeted therapies in metastatic renal cell carcinoma: overview of the past year.

Gross-Goupil M, Massard C, Ravaud A.

Curr Urol Rep. 2012 Feb;13(1):16-23. doi: 10.1007/s11934-011-0232-y. Review.

PMID:
22139625
7.

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C.

Lancet. 2012 Jan 7;379(9810):39-46. doi: 10.1016/S0140-6736(11)61226-9. Epub 2011 Nov 15.

8.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ.

Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Erratum in: Lancet. 2012 Nov 24;380(9856):1818.

PMID:
22056247
9.

Urothelial carcinomas: a focus on human epidermal receptors signaling.

Grivas PD, Day M, Hussain M.

Am J Transl Res. 2011 Aug 15;3(4):362-73. Epub 2011 Jul 25.

10.

Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?

Matsuguma H, Yoshino I, Ito H, Goya T, Matsui Y, Nakajima J, Ikeda N, Okumura S, Shiono S, Nomori H; Metastatic Lung Tumor Study Group of Japan.

Ann Thorac Surg. 2011 Aug;92(2):449-53. doi: 10.1016/j.athoracsur.2011.03.097.

PMID:
21801905
11.

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13728-33. doi: 10.1073/pnas.1107898108. Epub 2011 Jul 27.

12.

Survival after complete surgical resection of multiple metastases from renal cell carcinoma.

Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML.

Cancer. 2011 Jul 1;117(13):2873-82. doi: 10.1002/cncr.25836. Epub 2011 Jan 10.

13.

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Siegel R, Ward E, Brawley O, Jemal A.

CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.

14.

Abiraterone and increased survival in metastatic prostate cancer.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.

N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.

15.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A.

Ann Oncol. 2011 Dec;22(12):2646-53. doi: 10.1093/annonc/mdr023. Epub 2011 Mar 21.

PMID:
21427062
16.

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ; Hoosier Oncology Group.

J Clin Oncol. 2011 Apr 20;29(12):1525-30. doi: 10.1200/JCO.2010.31.6067. Epub 2011 Mar 21.

PMID:
21422406
17.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

18.

Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer.

Miyao N, Naito S, Ozono S, Shinohara N, Masumori N, Igarashi T, Nakao M, Tsushima T, Senga Y, Horie S, Kanayama HO, Tokuda N, Kobayashi M; Japanese Society of Renal Cancer.

Urology. 2011 Feb;77(2):379-84. doi: 10.1016/j.urology.2010.07.462. Epub 2010 Oct 23.

PMID:
20970828
19.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
20.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

Supplemental Content

Support Center